This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) | MicrobiomeTrials
← Back to trials NCT05263934
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Recruiting PHASE3 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2022-07-14Est. Completion: 2026-09-29
Enrollment target: 163 participantsLocations GSK Investigational Site, Denver, Colorado, United States GSK Investigational Site, Gainesville, Florida, United States GSK Investigational Site, Rochester, Minnesota, United States GSK Investigational Site, New York, New York, United States GSK Investigational Site, Charlotte, North Carolina, United States GSK Investigational Site, Pittsburgh, Pennsylvania, United States GSK Investigational Site, La Plata, Argentina GSK Investigational Site, San Miguel de Tucumán, Argentina GSK Investigational Site, Graz, Austria GSK Investigational Site, Santo André, Brazil GSK Investigational Site, São Paulo, Brazil GSK Investigational Site, Toronto, Ontario, Canada GSK Investigational Site, Toronto, Ontario, Canada GSK Investigational Site, Beijing, China GSK Investigational Site, Guangzhou, China GSK Investigational Site, Hefei, China GSK Investigational Site, Nanjing, China GSK Investigational Site, Qingdao, China Other microbiome trials you might be interested in Eosinophilic Granulomatosis With Polyangiitis (EGPA) Hypereosinophilia Syndrome (HES)
The main purpose of study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of benralizumab.
Aurora, United States Est. completion Feb 20, 2028
GPA Vasculitis Microscopic Polyangiitis (MPA) Churg-Strauss Syndrome (CSS)
The current state of knowledge on ANCA-associated vasculitis (AAV) indicates that it is a group of autoimmune diseases i…
Warsaw, Poland Est. completion Dec 31, 2026
GSK Investigational Site, Shanghai, China
GSK Investigational Site, Shenzhen, China
GSK Investigational Site, Wenzhou, China
GSK Investigational Site, La Roche-sur-Yon, France
GSK Investigational Site, Nantes, France
GSK Investigational Site, Paris, France
GSK Investigational Site, Freiburg im Breisgau, Germany
GSK Investigational Site, Minden, Germany
GSK Investigational Site, Ramat Gan, Israel
GSK Investigational Site, Bari, Italy
GSK Investigational Site, Brescia, Italy
GSK Investigational Site, Florence, Italy
GSK Investigational Site, Milan, Italy
GSK Investigational Site, Milan, Italy
GSK Investigational Site, Pavia, Italy
GSK Investigational Site, Pisa, Italy
GSK Investigational Site, Roma, Italy
GSK Investigational Site, Torrette AN, Italy
GSK Investigational Site, Treviso, Italy
GSK Investigational Site, Kanagawa, Japan
GSK Investigational Site, Kanagawa, Japan
GSK Investigational Site, Saitama, Japan
GSK Investigational Site, Tokyo, Japan
GSK Investigational Site, Tokyo, Japan
GSK Investigational Site, Groningen, Netherlands
GSK Investigational Site, Leiden, Netherlands
GSK Investigational Site, Gdansk, Poland
GSK Investigational Site, Lodz, Poland
GSK Investigational Site, Warsaw, Poland
GSK Investigational Site, Lisbon, Portugal
GSK Investigational Site, Porto, Portugal
GSK Investigational Site, Gwangju, South Korea
GSK Investigational Site, Seoul, South Korea
GSK Investigational Site, Seoul, South Korea
GSK Investigational Site, Seoul, South Korea
GSK Investigational Site, Seoul, South Korea
GSK Investigational Site, Barcelona, Spain
GSK Investigational Site, Barcelona, Spain
GSK Investigational Site, Granada, Spain
GSK Investigational Site, Pamplona, Spain
GSK Investigational Site, Zaragoza, Spain
GSK Investigational Site, Malmö, Sweden
GSK Investigational Site, Birmingham, United Kingdom
GSK Investigational Site, Cambridge, United Kingdom
GSK Investigational Site, London, United Kingdom